Trials / Completed
CompletedNCT00488761
Study Evaluating the Safety and Efficacy of Tigecycline in Hospitalized Patients With cSSSI
A Multicenter, Open Label Study to Evaluate the Safety and Efficacy of Tigecycline to Treat Complicated Skin and Skin Structure Infections (cSSSI) in Hospitalized Patients
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Tigecycline's activity against resistant organisms, as well as significant coverage of both gram-positive and gram-negative bacteria, may provide a valuable therapeutic alternative in treating patients with complicated skin and/or skin structure infections.
Detailed description
To evaluate the safety and the efficacy of tigecycline in treating hospitalized patients with complicated skin and/or skin structure infections.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tigecycline |
Timeline
- Start date
- 2006-07-01
- Completion
- 2007-08-01
- First posted
- 2007-06-20
- Last updated
- 2007-12-28
Locations
1 site across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT00488761. Inclusion in this directory is not an endorsement.